Plain-English translation of NCT07413523 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether adding stereotactic body radiation therapy (SBRT)—a precise, high-dose form of radiation—to standard cancer medications can help treat advanced bladder cancer that has spread to only a few other parts of the body. Right now, doctors mainly use chemotherapy and immunotherapy medications that work throughout the whole body. This study wants to see if combining those medications with targeted radiation to the specific areas where cancer has spread works better and is safe.
When bladder cancer spreads to other parts of the body, treatment options are limited and outcomes are often poor. This targeted radiation approach has worked well for other types of cancer that have spread in limited ways, but it hasn't been well studied in bladder cancer patients yet.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one group receives only standard cancer medications, while the other group receives those same medications plus the specialized radiation therapy directed at the areas where cancer has spread. If you are in the radiation group, you will receive several sessions of stereotactic radiation in addition to your regular cancer treatment visits. Throughout the study, you will have regular follow-up appointments to monitor how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Italy